Inactive Instrument

Foamix Pharmaceuticals Ltd. Share Price Nasdaq

IL0011334385

Valuation: Foamix Pharmaceuticals Ltd.

Market Cap	16.98M 14.91M 13.87M 12.72M 23.91M 1.63B 24.28M 165M 64.33M 804M 63.73M 62.36M 2.78B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	16.98M 14.91M 13.87M 12.72M 23.91M 1.63B 24.28M 165M 64.33M 804M 63.73M 62.36M 2.78B	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	-	Yield 2026 *	-	Yield 2027 *	-

* Estimated data More valuation ratios

Latest news : Foamix Pharmaceuticals Ltd.

07-24	Top Premarket Decliners	MT
07-21	VYNE Approves 1-for-50 Reverse Stock Split	MT
07-10	VYNE Therapeutics Inc. Declares Special Cash Dividend, Payable on July 23, 2026	CI
07-10	VYNE Therapeutics Declares Estimated $0.38-Per-Share Special Cash Dividend Ahead of Yarrow Merger	MT
05-15	VYNE Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
02-27	VYNE Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
12-18	RTW Biotech Opportunities announces new investment in Yarrow Bioscience	RE
12-17	VYNE Therapeutics Inc., Yarrow Bioscience, Inc. - M&A Call
12-17	Yarrow Bioscience, Inc. entered into an Agreement and Plan of Merger and Reorganization to acquire VYNE Therapeutics Inc. in a reverse merger transaction.	CI
12-17	Vyne Therapeutics and Yarrow Bioscience announce merger agreement	RE
11-06	VYNE Therapeutics Q3 net loss narrows, strategic review ongoing	RE
11-06	VYNE Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
14/08/25	VYNE Therapeutics Inc. Announces Resignation of Christine Borowski as Member of the Board and as A Member of the Nominating and Corporate Governance Committee	CI

More news

Last Transcript: Foamix Pharmaceuticals Ltd.

VYNE Therapeutics Inc., Yarrow Bioscience, Inc. - M&A Call

12-17

More transcripts

Analysts' recommendations: Foamix Pharmaceuticals Ltd.

31/07/25	BTIG Research Downgrades VYNE Therapeutics to Neutral From Buy	MT
18/11/24	BTIG Initiates VYNE Therapeutics at Buy With $8 Price Target	MT
12/05/23	Cantor Fitzgerald Adjusts Price Target on VYNE Therapeutics to $9 From $5, Maintains Overweight Rating	MT
14/03/23	HC Wainwright Adjusts Price Target on VYNE Therapeutics to $28 From $1.50, Maintains Buy Rating	MT
10/08/22	HC Wainwright Cuts VYNE Therapeutics' Price Target to $1.50 From $7, Maintains Buy Rating	MT

More recommendations

Press Releases: Foamix Pharmaceuticals Ltd.

07-23	VYNE Therapeutics Provides Update Regarding Cash Dividend, Reverse Stock Split and Anticipated Timing of Closing of the Proposed Merger with Yarrow Bioscience	AQ
07-21	VYNE Therapeutics Announces 1-for-50 Reverse Stock Split and Provides Update Regarding Special Dividend in Connection with the Proposed Merger with Yarrow Bioscience	AQ
07-10	VYNE Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Yarrow Bioscience	AQ
05-21	VYNE Therapeutics : Yarrow Bioscience Investor Presentation	PU
12-17	VYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement	AQ

More press releases

Managers and Directors: Foamix Pharmaceuticals Ltd.

Manager	Title	Age	Since
David Domzalski CEO	Chief Executive Officer	60	29/02/2020
Tyler Zeronda DFI	Director of Finance/CFO	40	-
Iain Stuart CTO	Chief Tech/Sci/R&D Officer	53	29/02/2020

Director	Title	Age	Since
David Domzalski BRD	Director/Board Member	60	29/02/2020
Sharon Barbari BRD	Director/Board Member	72	29/02/2020
Steven Basta BRD	Director/Board Member	61	31/12/2014

More insiders

VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need. It is developing VYN202, an oral, small molecule BD2-selective BET inhibitor. VYN202 is an oral, small molecule BD2-selective BET inhibitor that has been designed to achieve potential class-leading potency and selectivity for BD2 vs. BD1. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating.

Employees

Sector

Calendar

07-27 Significant Split/Dividend

More about the company

	2026 *	2027 *
Net sales	-	-
Net income	-50M -43.92M -40.84M -37.48M -70.41M -4.82B -71.5M -485M -189M -2.37B -188M -184M -8.18B	-75M -65.87M -61.26M -56.21M -106M -7.22B -107M -727M -284M -3.55B -282M -275M -12.28B
Net Debt	-	-